Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)
Previous Close
$1.73
52W Range
$1.10 - $43.35
50D Avg
$4.59
200D Avg
$10.27
Market Cap
$2.55M
Avg Vol (3M)
$113.73K
Beta
1.84
Div Yield
-
EIGR Company Profile
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
EIGR Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
NUVB | Nuvation Bio Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
FUSN | Fusion Pharmaceuticals Inc. |
APLT | Applied Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
SPRB | Spruce Biosciences, Inc. |
SPRO | Spero Therapeutics, Inc. |
FNCH | Finch Therapeutics Group, Inc. |
ETON | Eton Pharmaceuticals, Inc. |
CING | Cingulate Inc. |
TERN | Terns Pharmaceuticals, Inc. |
CNTB | Connect Biopharma Holdings Limited |
BOLT | Bolt Biotherapeutics, Inc. |
INZY | Inozyme Pharma, Inc. |
ELDN | Eledon Pharmaceuticals, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
UNCY | Unicycive Therapeutics, Inc. |
NLTX | Neurogene Inc. |
CHRS | Coherus BioSciences, Inc. |
LYRA | Lyra Therapeutics, Inc. |